Advertisement

Brachytherapy

  • Kenneth W. Angermeier
  • Jay P. Ciezki
Chapter
  • 138 Downloads
Part of the Current Clinical Urology book series (CCU)

Abstract

The concept of using radioactive isotopes for placement internally, i.e., brachytherapy, “in the practice of medicine for internal examinations or for destroying germs, microbes, bacteria, and the like” has been documented as early as 1903 in the United States Patent and Trademark Office (1). Various iterations in the techniques have emerged during the last century for treating prostate cancer with brachytherapy. The current transrectal ultrasound (TRUS)-guided techniques were first described in the mid-1980s (2). Since then, the technique has gained enough currency to be paired off against radical retropubic prostatectomy in a National Cancer Institute-sponsored protocol. This chapter reviews the more recent trends in implantation technique and also discusses patient selection, side effects, and efficacy.

Keywords

Radiat Oncol Biol Phys Localize Prostate Cancer Radical Retropubic Prostatectomy Cleveland Clinic Foundation Seed Implantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kunz GF. Luminous Composition. United States Patent Office. United States, 1905.Google Scholar
  2. 2.
    Blasko JC, Ragde H, Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether Hypertherm Oncol 1987; 3: 131.Google Scholar
  3. 3.
    Sohayda C, Kupelian PA, Levin HS, Klein EA. Extent of extracapsular extension in localized prostate cancer. Urology 2000; 55: 382–386.PubMedCrossRefGoogle Scholar
  4. 4.
    Davis BJ, Pisansky TM, Wilson TM, et al. The radial distance of extraprostatic extension of prostate carcinoma. Cancer 1999; 85: 2630–2637.PubMedCrossRefGoogle Scholar
  5. 5.
    D’Amico AV, Whittington R, Malkowicz B, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.PubMedCrossRefGoogle Scholar
  6. 6.
    Merrick GS, Butler WM, Galbreath RW, Lief JH. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1–T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001; 51: 41–48.PubMedCrossRefGoogle Scholar
  7. 7.
    Kwok Y, DiBiase SJ, Amin PP, Naslund M, Sklar G, Jacobs SC. Risk group stratification in patients undergoing permanent I-125 prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 2002; 53: 588–594.PubMedCrossRefGoogle Scholar
  8. 8.
    Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 31–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Potters L, Cha C, Oshinsky G, Venkatramen E, Zelefsky M, Leibel S. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 1999; 5: 301–306.PubMedGoogle Scholar
  10. 10.
    Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 47: 1261–1266.PubMedCrossRefGoogle Scholar
  11. 11.
    Nag S, Beyer D, Friedland J, Grimm P, Nath R. American brachytherapy society (ABS) recommendations for transperineal placement brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999; 44: 789–799.PubMedCrossRefGoogle Scholar
  12. 12.
    Butzbach D, Waterman FM, Dicker AP. Can extraprostatic extension be treated by pro vstate brachytherapy? An analysis based on postimplant dosimetry. Int J Radiat Oncol Biol Phys 2001; 51: 1196–1199.PubMedCrossRefGoogle Scholar
  13. 13.
    Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 839–850.PubMedCrossRefGoogle Scholar
  14. 14.
    Potters L, Fearn P, Kattan MW. External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. Brachytherapy 2002; 1: 36–4 1.Google Scholar
  15. 15.
    Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998: 1379–1382.Google Scholar
  16. 16.
    Elshaikh MA, Angermeier K, Ulchaker JC, et al. Effect of anatomic, procedural, and dosimetric variables on urinary retention after permanent iodine-125 prostate brachytherapy. Urology 2003; 61: 152–155.PubMedCrossRefGoogle Scholar
  17. 17.
    Wallner K, Lee H, Wasserman S, Dattoli M. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997; 37: 565–569.PubMedCrossRefGoogle Scholar
  18. 18.
    Wilkinson DA, Lee EJ, Ciezki JP, et al. Dosimetric comparison of pre-planned and OR-planned prostate seed brachytherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1241–1244.PubMedCrossRefGoogle Scholar
  19. 19.
    Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys 2002; 54: 1063–1068.PubMedCrossRefGoogle Scholar
  20. 20.
    Vicini FA, Martinez A, Hanks G, et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer 2002; 95: 2041–2043.CrossRefGoogle Scholar
  21. 21.
    Cox J, Grognon D, Kaplan R, Parsons J, Schellhammer P. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035–1041.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Kenneth W. Angermeier
  • Jay P. Ciezki

There are no affiliations available

Personalised recommendations